European heart journal open最新文献

{"title":"Utility of electrocardiographic findings in acute pulmonary embolism.","authors":"Alexander E Sullivan, Tara A Holder, Joshua A Beckman, Cynthia L Green, Manesh R Patel, Terry A Fortin, W Schuyler Jones","doi":"10.1093/ehjopen/oead121","DOIUrl":"10.1093/ehjopen/oead121","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead121"},"PeriodicalIF":0.0,"publicationDate":"2023-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to assess haemodynamic impact of atrial fibrillation.","authors":"Naoya Kataoka, Teruhiko Imamura","doi":"10.1093/ehjopen/oead123","DOIUrl":"https://doi.org/10.1093/ehjopen/oead123","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead123"},"PeriodicalIF":0.0,"publicationDate":"2023-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10726916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women in Cardiology.","authors":"Salvatore De Rosa, Margarita Brida, Julia Grapsa, Laura Dos Subira, Magnus Bäck, Alaide Chieffo","doi":"10.1093/ehjopen/oead122","DOIUrl":"10.1093/ehjopen/oead122","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead122"},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study.","authors":"Ioannis Katsoularis, Hanna Jerndal, Sebastian Kalucza, Krister Lindmark, Osvaldo Fonseca-Rodríguez, Anne-Marie Fors Connolly","doi":"10.1093/ehjopen/oead120","DOIUrl":"https://doi.org/10.1093/ehjopen/oead120","url":null,"abstract":"<p><strong>Aims: </strong>COVID-19 increases the risk of cardiovascular disease, especially thrombotic complications. There is less knowledge on the risk of arrhythmias after COVID-19. In this study, we aimed to quantify the risk of arrhythmias following COVID-19.</p><p><strong>Methods and results: </strong>This study was based on national register data on all individuals in Sweden who tested positive for SARS-CoV-2 between 1 February 2020 and 25 May 2021. The outcome was incident cardiac arrhythmias, defined as international classification of diseases (10th revision) codes in the registers as follows: atrial arrhythmias; paroxysmal supraventricular tachycardias; bradyarrhythmias; and ventricular arrhythmias. A self-controlled case series study and a matched cohort study, using conditional Poisson regression, were performed to determine the incidence rate ratio and risk ratio, respectively, for an arrhythmia event following COVID-19.A total of 1 057 174 exposed (COVID-19) individuals were included in the study as well as 4 074 844 matched unexposed individuals. The incidence rate ratio of atrial tachycardias, paroxysmal supraventricular tachycardias, and bradyarrhythmias was significantly increased up to 60, 180, and 14 days after COVID-19, respectively. In the matched cohort study, the risk ratio during Days 1-30 following COVID-19/index date was 12.28 (10.79-13.96), 5.26 (3.74-7.42), and 3.36 (2.42-4.68), respectively, for the three outcomes. The risks were generally higher in older individuals, in unvaccinated individuals, and in individuals with more severe COVID-19. The risk of ventricular arrhythmias was not increased.</p><p><strong>Conclusion: </strong>There is an increased risk of cardiac arrhythmias following COVID-19, and particularly increased in elderly vulnerable individuals, as well as in individuals with severe COVID-19.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead120"},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased cardiovascular mortality during the COVID-19 pandemic: do not neglect causality.","authors":"Bente Halvorsen, Pål Aukrust, Tuva Børresdatter Dahl, Ida Gregersen","doi":"10.1093/ehjopen/oead119","DOIUrl":"https://doi.org/10.1093/ehjopen/oead119","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead119"},"PeriodicalIF":0.0,"publicationDate":"2023-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10711536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Posterior Pericardiotomy on the Incidence of Atrial Fibrillation After Cardiac Surgery-Extended Follow-Up study (PALACS-EF): rationale and design.","authors":"Mario Gaudino, Lamia Harik, Bjorn Redfors, Sigrid Sandner, John H Alexander, Antonino Di Franco, Arnaldo Dimagli, Jonathon Weinsaft, Roberto Perezgrovas-Olaria, Giovanni Jr Soletti, Christopher Lau, Charles Mack, Leonard Girardi","doi":"10.1093/ehjopen/oead118","DOIUrl":"10.1093/ehjopen/oead118","url":null,"abstract":"<p><strong>Aims: </strong>Postoperative atrial fibrillation (POAF) is the most common complication of cardiac surgery and has been associated with increased postoperative morbidity and hospital costs. The Posterior left pericardiotomy for the prevention of AtriaL fibrillation After Cardiac Surgery (PALACS) trial found that posterior pericardiotomy significantly reduced the incidence of POAF (17% vs. 32%, <i>P</i> < 0.001). We present the protocol for The Effect of Posterior Pericardiotomy on the Incidence of Atrial Fibrillation After Cardiac Surgery-Extended Follow-Up study (PALACS-EF): a prospective, extended follow-up of the original PALACS trial. The aim of PALACS-EF is to gain more data regarding the effect of posterior pericardiotomy on postdischarge clinical outcomes. The primary outcome is the time to the first occurrence of the composite of all-cause mortality or hospital cardiovascular readmission. The key secondary outcome is the time to the first occurrence of the composite of all-cause mortality and all-cause hospital readmission. Hospital readmission, myocardial infarction, stroke, transient ischaemic attack, heart failure, systemic embolism, or new arrhythmias with onset since 30-day follow-up will also be recorded.</p><p><strong>Methods and results: </strong>All 420 patients enrolled in the PALACS trial will be included; extended follow-up will be conducted via telephone by blinded research personnel utilizing a standardized script to ensure uniformity and completeness of follow-up. If an event has occurred, documentation will be obtained, and an independent adjudication committee blinded to group assignment will adjudicate outcome events. Results will be reported when a median follow-up of 5 years is achieved.</p><p><strong>Conclusion: </strong>PALACS-EF will provide data to answer the question of whether posterior pericardiotomy improves postdischarge outcomes in patients undergoing cardiac surgery, and it will provide information on the relationship between POAF and adverse postdischarge outcomes including mortality, hospitalization, heart failure, and stroke.</p><p><strong>Registration: </strong>PALACS: NCT02875405, PALACS-EF: NCT05903222.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead118"},"PeriodicalIF":0.0,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventing immortal time bias in observational studies: a matter of design.","authors":"Bart J J Velders, Michiel D Vriesendorp, Rolf H H Groenwold","doi":"10.1093/ehjopen/oead117","DOIUrl":"10.1093/ehjopen/oead117","url":null,"abstract":"We thank Diab and colleagues for raising awareness for immortal time bias (ITB) in studies on cardiosurgical treatments in the European Heart Journal. 1 The authors elaborate on ITB in research on infective endocarditis (IE) and tricuspid regurgitation (TR), stating that a prospective, intention-to-treat design is the only practical way to detect and avoid ITB. In this letter, we elaborate on the causes of ITB and outline additional methods to prevent this bias in observational studies. ITB is introduced when researchers deviate from basic principles of study design. At the start of follow-up (i.e. ‘time-zero’), treatment status should be determined and eligibility criteria should be met for all participants. For a fair comparison, time-zero","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"3 6","pages":"oead117"},"PeriodicalIF":0.0,"publicationDate":"2023-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transradial Intervention in Dialysis Patients Undergoing Percutaneous Coronary Intervention: A Japanese Nationwide Registry Study","authors":"Toshiki Kuno, Kyohei Yamaji, Tadao Aikawa, Mitsuaki Sawano, Tomo Ando, Yohei Numasawa, Hideki Wada, Tetsuya Amano, Ken Kozuma, Shun Kohsaka","doi":"10.1093/ehjopen/oead116","DOIUrl":"https://doi.org/10.1093/ehjopen/oead116","url":null,"abstract":"Abstract Background Transradial intervention (TRI) for percutaneous coronary intervention (PCI) is used to reduce periprocedural complications. However, its effectiveness and safety for patients on dialysis are not well established. Aims We aimed to investigate the association of TRI with in-hospital complications in dialysis patients undergoing PCI. Methods We included 44,462 patients on dialysis who underwent PCI using Japanese nationwide PCI registry data (2019–2021) regardless of acute or chronic coronary syndrome. Patients were categorized based on access site: TRI, transfemoral intervention (TFI). Periprocedural access site bleeding complication requiring transfusion was the primary outcome and in-hospital death and other periprocedural complications were the secondary outcomes. Matched weighted analysis was performed for TRI and TFI. Results Here, 8,267 (18.6%) underwent TRI, 36,195 (81.4%) underwent TFI, . Patients who received TRI were older and had lower rates of comorbidities than those who received TFI. Access site bleeding rate and in-hospital death were significantly lower in the TRI group (0.1% versus 0.7%, P &amp;lt; 0.001; 1.8% versus 3.2%, P &amp;lt; 0.001, respectively). After adjustment, TRI was associated with a lower risk of access site bleeding (odds ratio [OR] [95% confidence interval (CI)]: 0.19 [0.099–0.38]; P &amp;lt; 0.001) and in-hospital death (OR [95% CI]: 0.79 [0.65–0.96]; P = 0.02). Other periprocedural complications between TRI and TFI were not significantly different. Conclusions In patients undergoing dialysis and PCI, TRI had a lower risk of access site bleeding and in-hospital death than TFI. This suggests that TRI may be safer for this patient population.","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"101 11","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134957612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in Patients with Metabolic Syndrome, but without Diabetes: REDUCE-IT MetSyn","authors":"Michael Miller, Deepak L Bhatt, Eliot A Brinton, Terry A Jacobson, Ph Gabriel Steg, Armando Lira Pineda, Steven B Ketchum, Ralph T Doyle, Jean-Claude Tardif, Christie M Ballantyne","doi":"10.1093/ehjopen/oead114","DOIUrl":"https://doi.org/10.1093/ehjopen/oead114","url":null,"abstract":"Abstract Introduction Metabolic Syndrome (MetSyn) is associated with high risk of cardiovascular (CV) events, irrespective of statin therapy. In the overall REDUCE-IT study of statin-treated patients, icosapent ethyl (IPE) reduced the risk of the primary composite endpoint (CV death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization) and the key secondary composite endpoint (CV death, nonfatal myocardial infarction, or nonfatal stroke). Methods REDUCE-IT was an international, double-blind trial that randomized 8179 high CV risk statin-treated patients with controlled low density lipoprotein cholesterol (LDL-C), and elevated triglycerides, to IPE 4 grams/day or placebo. The current study evaluated the prespecified patient subgroup with a history of MetSyn, but without diabetes at baseline. Results Among patients with MetSyn but without diabetes at baseline (n=2866), the majority (99.8%) of this subgroup were secondary prevention patients. IPE use was associated with a 29% relative risk reduction for the first occurrence of the primary composite endpoint (hazard ratio [HR], 0.71 [95% CI, 0.59-0.84]; P &amp;lt;0.0001, absolute risk reduction [ARR]=5.9%; number needed to treat [NNT]=17) and 41% reduction in total (first plus subsequent) events (rate ratio [RR], 0.59 [95% CI, 0.48-0.72]; P &amp;lt;0.0001) compared with placebo. The risk for the key secondary composite endpoint was reduced by 20% (P=0.05) and a 27% reduction in fatal/nonfatal MI (P=0.03), 47% reduction in urgent/emergent revascularization (P &amp;lt;0.0001) and 58% reduction in hospitalization for unstable angina (P &amp;lt;0.0001). Non-statistically significant reductions were observed in cardiac arrest (44%) and sudden cardiac death (34%). Conclusion(s) In statin-treated patients with a history of MetSyn, IPE significantly reduced the risk of first and total CV events in REDUCE-IT. The large relative and absolute risk reductions observed supports IPE as a potential therapeutic consideration for patients with MetSyn at high CV risk.","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"8 7","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135037976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome cardiovascular risk prevention by omega-3 polyunsaturated fatty acids","authors":"Magnus Bäck, Roberto Latini","doi":"10.1093/ehjopen/oead115","DOIUrl":"https://doi.org/10.1093/ehjopen/oead115","url":null,"abstract":"high-dose","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"28 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135037275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}